1,386 results on '"Tiseo, Marcello"'
Search Results
302. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
303. SHORT HYDRATION REGIMEN AND NEPHROTOXICITY OF INTERMEDIATE TO HIGH-DOSE CISPLATIN-BASED CHEMOTHERAPY FOR OUTPATIENT TREATMENT IN LUNG CANCER AND MESOTHELIOMA
304. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer
305. Platinum-Based Versus Non–Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference?
306. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
307. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
308. Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib
309. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
310. 60 - Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L
311. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
312. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
313. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
314. Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study
315. The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies
316. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
317. Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
318. How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer
319. Wide and Cystic Brain Metastases Reveal RET-Rearranged Non–Small-Cell Lung Cancers
320. Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?
321. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
322. Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach
323. Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
324. Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L
325. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
326. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion
327. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study
328. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
329. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
330. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial
331. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer
332. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
333. Abstract 4887: RecurrentNRG1rearrangements in Caucasian pulmonary mucinous adenocarcinoma: results from an Italian multi-center cohort
334. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine
335. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
336. Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.
337. Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.
338. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
339. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
340. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
341. Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine
342. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer
343. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
344. Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review
345. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
346. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
347. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
348. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
349. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions
350. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.